ArticleJournal of cellular and molecular medicine2024
Anemoside B4 alleviates arthritis pain via suppressing ferroptosis-mediated inflammation.
Article in Journal of cellular and molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 15 citations in OpenAlex.
- Anemoside B4 inhibits mitochondrial dysfunction-related mitophagy in asthma by regulating KAT2B/IRF3 axis.Molecular and cellular biochemistry · 2026Article
- Inhibiting pyruvate carboxylase as a potential therapeutic strategy for alleviating rheumatoid arthritis.Inflammopharmacology · 2026Article
- Targeting Ferroptosis With Natural Products for the Treatment of Skeletal System Disease: An Updated Review.Journal of cellular and molecular medicine · 2026Review
- Mechanical cues as immunomodulators in neuroinflammation-driven spinal sensitization: analgesic mechanisms and therapeutic strategies.Frontiers in immunology · 2026Review
- Article
- Screening drugs of Anemoside B4 for MFAP4 expression in osteosarcoma in PDTX to increase personalized medicine.Discover oncology · 2025Article
- Nanodrug delivery systems targeting ferroptosis as an innovative therapeutic approach for Rheumatoid Arthritis.Materials today. Bio · 2025Review
- Camellia Tea Saponin Ameliorates 5-Fluorouracil-Induced Damage of HaCaT Cells by Regulating Ferroptosis and Inflammation.Nutrients · 2025Article
- Anemoside B4 targets RAGE to attenuate ferroptosis in sepsis-induced acute lung injury.Frontiers in pharmacology · 2025Article
- Ferroptosis in pain: evidence, challenges, and opportunities.Frontiers in immunology · 2025Review
- Triterpenoid Compounds and their Derivatives: Emerging Pharmacological Agents for Arthritis Treatment.Mini reviews in medicinal chemistry · 2025Review
- Ferroptosis: New Strategies for Clinical Treatment of Rheumatoid Arthritis.Journal of inflammation research · 2025Review
- Effect of anemoside B4 on ameliorating cerebral ischemic/reperfusion injury.Iranian journal of basic medical sciences · 2025Article
- GSK3-Driven Modulation of Inflammation and Tissue Integrity in the Animal Model.International journal of molecular sciences · 2024Review
- Ferroptosis in Arthritis: Driver of the Disease or Therapeutic Option?International journal of molecular sciences · 2024Review
- Anemoside B4 alleviates arthritis pain via suppressing ferroptosis-mediated inflammation.Journal of cellular and molecular medicine · 2024Article
- Contemporary insights and prospects on ferroptosis in rheumatoid arthritis management.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Chronic pain is the key manifestations of rheumatoid arthritis. Neuroinflammation in the spinal cord drives central sensitization and chronic pain. Ferroptosis has potentially important roles in the occurrence of neuroinflammation and chronic pain. In the current study, mouse model of collagen-induced arthritis was established by intradermal injection of type II collagen in complete Freund's adjuvant (CFA) solution. CFA inducement resulted in swollen paw and ankle, mechanical and spontaneous pain, and impaired motor coordination. The spinal inflammation was triggered, astrocytes were activated, and increased NLRP3-mediated inflammatory signal was found in CFA spinal cord. Oxidative stress and ferroptosis in the spinal cord were manifested. Meanwhile, enhancive spinal GSK-3β activity and abnormal phosphorylated Drp1 were observed. To investigate the potential therapeutic options for arthritic pain, mice were intraperitoneally injected with AB4 for three consecutive days. AB4 treatment reduced pain sensitivity and increased the motor coordination. In the spinal cord, AB4 treatment inhibited NLRP3 inflammasome-mediated inflammatory response, increased antioxidation, decreased mitochondrial reactive oxygen species and ferroptosis. Furthermore, AB4 decreased GSK-3β activity by binding with GSK-3β through five electrovalent bonds. Our findings indicated that AB treatment relieves arthritis pain by inhibiting GSK-3β activation, increasing antioxidant capability, reducing Drp1-mediated mitochondrial dysfunction and suppressing neuroinflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.